featured
Efficacy and Safety of Sovleplenib in Adults With Chronic Primary Immune Thrombocytopenia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Lancet Haematol 2024 Jun 13;[EPub Ahead of Print], Y Hu, X Liu, H Zhou, S Wang, R Huang, Y Wang, X Du, J Sun, Z Zhou, Z Yan, W Chen, W Wang, Q Liu, Q Zeng, Y Gong, J Yin, X Shen, B Ye, Y Chen, Y Xu, H Sun, Y Cheng, Z Liu, C Wang, G Yuan, X Zhang, X Li, P Cheng, X Guo, Z Jiang, F Yang, L Yang, C Luo, T Xiao, S Fu, H Yin, X Guo, Q Xu, S Fan, MM Shi, W Su, H Mei, R YangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.